This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
CAMP HILL, Pa., July 11, 2018 (GLOBE NEWSWIRE) -- Harsco Corporation (NYSE:HSC) today announced that it will issue its second quarter 2018 earnings results on Thursday, August 2, 2018 prior to NYSE market open via newswire distribution and a posting on the company website at www.harsco.com.
Investors focused on the Industrial Products space have likely heard of Harsco (HSC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Tetra Tech, Inc. (TTEK - Free Report) recently announced that the company has secured a $60-million multiple-award contract from the U.S. Army Corps of Engineers, Portland District. Per the five-year contract, Tetra Tech will provide engineering and design services throughout the Pacific Northwest.
HSC GGG TTEK WBT PII
The Zacks Rank has proven to be a valuable resource for experienced and beginning investors alike. This is because the model is simple; it identifies stocks that are poised to outperform the market over the next one to three months by harnessing the power of earnings estimates and earnings estimate revisions.
HD HSC ILMN YY
CAMP HILL, Pa., June 18, 2018 (GLOBE NEWSWIRE) -- Harsco Corporation (NYSE:HSC) (the “Company”) announced today amendments to its existing senior secured credit facilities in order to, among other things, reduce the interest rate applicable to the $545 million of term loans outstanding and increase the amount of its revolving credit commitments. Goldman Sachs and Citigroup acted as joint bookrunners and joint lead arrangers for the amendments.
Investors focused on the Industrial Products space have likely heard of Harsco (HSC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Industrial Products peers, we might be able to answer that question.
HSC SPG.PRJ SPG
The Zacks methodology is one that is designed to provide investors—whether they are beginners to the market or have decades of knowledge—with the best chances to find strong stocks at any given moment. To do this, we have designed the Zacks Rank, a system which harnesses the power of earnings estimate revisions to find companies on the rise.
ELY HSC CSX YY
Investors are always on the lookout for a winning strategy, which is easier said than done. When markets are rattled by widespread global growth concerns, it is difficult for even the most perceptive investors to come up with a foolproof plan. No matter how disciplined and systematic investors are, equity market volatility will always manage to get the better of them. While a few lucky ones rake in the moolah, others fall victim to ad hoc strategies.
HSC MNESP TPB MSA WTW ENVA JOUT
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to HSC / Harsco Corp. on message board site Silicon Investor.
|HSCC - Homeland Security Corp||Canadian Hot Stock Club - CHSC|
|GGNC: A Rothschildian Perspective||Housecall Medical (HSCL)|
as of ET